Atrantil for Small Intestinal Bacterial Overgrowth
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the supplement Atrantil to determine its effectiveness for individuals with Intestinal Methane Overgrowth (IMO), a condition caused by excessive methane-producing bacteria in the gut. These bacteria can cause symptoms such as bloating, abdominal pain, and constipation. The trial aims to discover if Atrantil can reduce symptoms and improve quality of life for those affected. Individuals who frequently experience bloating and abdominal pain and are patients at Northwestern Memorial Hospital might be suitable candidates for this trial. As an unphased trial, this study provides a unique opportunity to contribute to scientific understanding and potentially find relief from uncomfortable symptoms.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that Atrantil is likely to be safe for humans?
Research has shown that Atrantil is usually easy for people to take. In a past study involving individuals with irritable bowel syndrome with constipation, participants reported no side effects, indicating that the supplement is well-tolerated. Although Atrantil has no known side effects, some people might experience a "die-off" reaction. This occurs when harmful bacteria die off quickly, temporarily causing flu-like symptoms. Overall, Atrantil is considered safe and is certified gluten-free for those with sensitivities.12345
Why are researchers excited about this trial?
Atrantil is unique because it targets intestinal bacterial overgrowth with a blend of polyphenols, which are natural compounds found in plants. Unlike antibiotics that aim to kill bacteria, Atrantil works by reducing the production of methane gas in the gut, which can alleviate bloating and discomfort. This approach offers a plant-based alternative that may have fewer side effects and avoid the issue of antibiotic resistance. Researchers are excited about Atrantil's potential to provide relief while being gentle on the digestive system.
What evidence suggests that Atrantil might be an effective treatment for Intestinal Bacterial Overgrowth?
Research has shown that Atrantil may help alleviate symptoms of Intestinal Bacterial Overgrowth (IBO). In one study, 80% of patients experienced relief from bloating, constipation, and stomach discomfort after using Atrantil. Another report found an 88% success rate in reducing bloating and stomach pain. Atrantil targets certain gut bacteria, potentially lowering methane levels and improving symptoms. Early findings suggest it could be a promising alternative to antibiotics for some individuals. In this trial, participants will take two capsules of Atrantil three times a day for 28 days to further evaluate its effectiveness.26789
Who Is on the Research Team?
Darren Brenner, MD
Principal Investigator
Northwestern Memorial Hospital/Feinberg School of Medicine
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants take two capsules of Atrantil three times a day for 28 days
Follow-up
Participants are monitored for changes in quality of life and clinical symptoms after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Atrantil
Find a Clinic Near You
Who Is Running the Clinical Trial?
Northwestern University
Lead Sponsor